Protalix BioTherapeutics, Inc. (de) · AMEX:PLX

Protalix BioTherapeutics, Inc. (de) — Q3 2026 Earnings Presentation

25 slides from Protalix BioTherapeutics, Inc. (de)'s earnings presentation, Nov 10, 2026

  1. Slide 1: Protalix BioTherapeutics Corporate Presentation

    PROTALIX BIOTHERAPEUTICS Pioneering solutions to transform the treatment of rare diseases PROTALIX BIOTHERAPEUTICS CO C OR RPPO O RR AA TT EE PPRREESSE EN NT T AATT I OI O NN J uo nv ee m2b0e2r 4 2 0 2 6 N 1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Third-Party Information This presentation contains forward-looking statements that involve risks and uncertainties within the meaning of Section 27A of the This presentation also contains estimates and other Securities Act of 1933, as amended, or the Securities Act, and Se

  3. Slide 3: Experienced leadership team

    CORPORATE OVERVIEW Experienced leadership team Dror Bashan YARON NAOS President and CEO SVP & COO Mr. Bashan has >25 years of experience in the Mr. Naos has been with Protalix for >20 years. He has a pharmaceutical industry, including close to 20 years at Teva, wealth of hands-on experience and know

  4. Slide 4: Accomplished Board of Directors

    CORPORATE OVERVIEW Accomplished Board of Directors ELIOT FORSTER, DROR BASHAN POL F. BOUDES, GWEN A. PH.D. President & CEO, M.D. MELINCOFF Chairman Director Director Director AHARON AMOS BAR SHMUEL “MULI” SCHWARTZ, CHRISTIAN ELSE SHALEV BEN ZVI, PH.D. PH.D. Director Director Director Director BATM l

  5. Slide 5: Protalix delivers innovations from concept to market

    CORPORATE OVERVIEW Protalix delivers innovations from concept to market Proven execution of delivering protein products for rare diseases with a pipeline for the future Revenue generating Next phase of the company Partnered commercial products PRX-115 potential best-in-class Pipeline for the future

  6. Slide 6: Two commercial products and a growing pipeline for the future

    CORPORATE OVERVIEW Two commercial products and a growing pipeline for the future Developing recombinant proteins for rare diseases with unmet medical needs Discovery Marketing Indication Phase 1 Phase 2 Phase 3 Status and Preclinical Application Commercial portfolio Approved in the US, Fabry Disease

  7. Slide 7: Well-capitalized to advance Protalix to the next phase

    CORPORATE OVERVIEW Well-capitalized to advance Protalix to the next phase Net income of $26.1 million for the first nine months of 2026 Total revenues increased by $32.0 million year to date to $75.6 million, from REVENUES $43.6 million for the same period in 2025 CASH & CASH RUNWAY $48.5M (as of Se

  8. Slide 8: Phase 2 RELEASE actively enrolling

    Phase 2 RELEASE Actively enrolling PRX-115 for uncontrolled gout: top-line results from Phase 2 RELEASE trial expected in 2H 2027 8

  9. Slide 9: Uncontrolled gout is severe; PRX-115 aims to deliver rapid, durable control

    GOUT DISEASE STATE Uncontrolled gout is severe; PRX-115 aims to deliver rapid, durable control How elevated plasma uric acid becomes uncontrolled gout, and where PRX-115 could fit What is gout? What is uncontrolled gout? Where PRX-115 could fit Elevated plasma uric acid Severe condition despite Rapi

  10. Slide 10: ~180,000 US patients qualify for uricase; 6-8K receive Krystexxa

    PRX-115 GOUT OPPORTUNITY IN UNCONTROLLED GOUT ~180,000 US patients qualify for uricase; 6-8K receive Krystexxa Gout Seek treatment Referred to Uncontrolled patients at PCP rheumatologists gout Krystexxa® 11.3M1 5M2 1.2M2 ~180,0003 6-8K4 Uricase Treatments URAT1s** allopurinol, febuxostat Market pois

  11. Slide 11: PRX-115 aims to address the unmet needs of current uricase therapy

    UNMET NEED AND HOW PRX-115 COULD HAVE ADVANTAGE PRX-115 aims to address the unmet needs of current uricase therapy Each unmet need maps to a PRX-115 design feature or study element Infusion logistics and burden RELEASE study tests dosing every 4 to 8 weeks Immunogenicity and loss of efficacy PEG des

  12. Slide 12: Phase 1 escalated PRX-115 across eight single-dose cohorts

    PRX-115 PHASE 1 TRIAL Phase 1 escalated PRX-115 across eight single-dose cohorts Recombinant PEGylated uricase enzyme produced via ProCellEx® Cohort 8: 36 mg Population Single ascending dose Subjects with N = 8 per cohort Cohort 7: 24 mg 6 PRX-115 and 2 placebo elevated plasma Cohort 6: 18 mg uric a

  13. Slide 13: A single infusion held mean plasma uric acid below 6.0 mg/dL for up to 12 weeks

    PRX-115 PHASE 1 TRIAL A single 36 mg infusion held mean plasma uric acid below 6.0 mg/dL for up to 12 weeks 4 of 6 participants were below 2 mg/dL at week 8, the basis for testing every 8 weeks in RELEASE ACR Convergence 2024 poster: ACR Convergence 2026: mean plasma uric acid by dose cohort ¹ indiv

  14. Slide 14: Safety summary: PRX-115 was generally well tolerated in Phase 1

    PRX-115 PHASE 1 TRIAL Safety summary: PRX-115 was generally well tolerated in Phase 1 Supporting continued development in Phase 2 study Generally well tolerated Phase 1 single ascending dose study; related adverse events were mostly mild to moderate and transient One anaphylactic reaction, which res

  15. Slide 15: PRX-115 Phase 2 double blind placebo-controlled study design

    PRX-115 PHASE 2 RELEASE STUDY PRX-115 Phase 2 double blind placebo-controlled study design: actively enrolling Fixed Dose at Various Dosing Intervals Study population and endpoints PRX-115 IV Dosing Regimens and Treatment Arms Patient Population: uncontrolled gout Arm A* every 4 weeks w/o MTX N=30 P

  16. Slide 16: PRX-115 aims to lower infusion burden: every 8 weeks with methotrexate, every 4 weeks without

    GOUT COMPETITIVE LANDSCAPE AND DOSING PRX-115 aims to lower infusion burden: every 8 weeks with methotrexate, every 4 weeks without Dosing schedule over 24 weeks Approved in the U.S. Not approved (investigational) APPROVED IN THE U.S. Krystexxa Every 2 weeks; with weekly oral MTX Marketed NOT APPROV

  17. Slide 17: Commercial products

    Commercial products Reliably partnered and delivering revenue 17

  18. Slide 18: Two commercial products sustaining future growth

    PARTNERED COMMERCIAL PORTFOLIO Two commercial products sustaining future growth Enzyme replacement therapies (ERTs) are an established treatment for lysosomal storage diseases Fabry disease Gaucher disease Rare X-linked disorder (~1/40,000-60,000 males WW) with Rare autosomal recessive disorder (~1/

  19. Slide 19: Every-4-weeks Elfabrio dosing for adults with Fabry disease is an advantage

    PARTNERED COMMERCIAL PORTFOLIO Every-4-weeks (E4W) Elfabrio® dosing for adults with Fabry disease is an advantage1 Reduces treatment burden from standard bi-weekly regimens Infusions per year Elfabrio® E4W dosing clinically validated BRIGHT study Quality-of-life • E4W maintained clinical and renal o

  20. Slide 20: Fabry disease competitive landscape

    PARTNERED COMMERCIAL PORTFOLIO Fabry disease competitive landscape ~$2.2B market (2025) expected to reach over ~$3.2B (2031), CAGR of 6.4%1 Product Name Fabrazyme® Replagal® Galafold®2 Elfabrio® Parent Company ERT Mechanism ERT ERT Pharmacological chaperone longer half-life (pegylated) Adults & pedi

  21. Slide 21: Chiesi Rare Diseases sales grew 22.3% to €906M in 2025

    PARTNERED COMMERCIAL PORTFOLIO Chiesi Rare Diseases sales grew 22.3% to €906M in 2025 Global partner for Elfabrio1 • International research-focused biopharmaceutical group with sales of €3.6B in 2025 (reflecting 8% growth year-on-year) • Air (respiratory) - €1.9B, Rare - €906M (22.3% growth), Care (

  22. Slide 22: Growth strategy

    Growth strategy Next phase of the company 22

  23. Slide 23: Patent portfolio for Elfabrio and PRX-115

    INTELLECTUAL PROPERTY Patent portfolio for Elfabrio and PRX-115 15 ~72 ~35 patent families patents worldwide pending applications Elfabrio® (pegunigalsidase alfa-iwxj) PRX-115 (PEGylated uricase) 2035¹ 2041² U.S. expiration, including the Patent Term Extension Nominal expiration of the modified uric

  24. Slide 24: Research strategy - leveraging internal strengths to fuel the company's next phase

    GROWTH STRATEGY Research strategy - leveraging internal strengths to fuel the company's next phase Proven ability to drive discovery, development, and registration of new drugs Rare renal disease focus 3-year goal • ADPKD, Alport, FSGS, others 5-7 programs spanning • Modality agnostic: nucleic acids

  25. Slide 25: A growing commercial base with PRX-115 top-line results expected in 2H 2027

    GROWTH STRATEGY A growing commercial base with PRX-115 top-line results expected in 2H 2027 Today: a growing commercial base Next: pipeline for growth USD 48.5M PRX-115 in uncontrolled gout USD 75.6M Cash, cash equivalents Total revenues, and short-term deposits, • Potential best-in-class uricase fi

Protalix BioTherapeutics, Inc. (DE) — Q3 2026 Earnings Presentation on 6ix